TG THERAPEUTICS ($TGTX) posted quarterly earnings results for Q3 2026 on Monday, November 9th. The company reported earnings of $0.35 per share, missing estimates of $0.37 by $0.02. The company also reported revenue of $259,940,000, beating estimates of $250,384,500 by $9,555,500.
You can see Quiver Quantitative's $TGTX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
TG THERAPEUTICS Insider Trading Activity
TG THERAPEUTICS insiders have traded $TGTX stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $TGTX stock by insiders over the last 6 months:
- LAURENCE N CHARNEY sold 5,000 shares for an estimated $274,800
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
TG THERAPEUTICS Hedge Fund Activity
We have seen 227 institutional investors add shares of TG THERAPEUTICS stock to their portfolio, and 172 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- D. E. SHAW & CO., INC. added 2,700,463 shares (+385.6%) to their portfolio in Q2 2026, for an estimated $148,363,437
- PRICE T ROWE ASSOCIATES INC /MD/ added 2,134,922 shares (+337.4%) to their portfolio in Q2 2026, for an estimated $117,292,614
- BARCLAYS PLC added 1,465,946 shares (+153.0%) to their portfolio in Q3 2026, for an estimated $81,770,467
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,313,103 shares (+inf%) to their portfolio in Q2 2026, for an estimated $72,141,878
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 1,101,424 shares (-27.3%) from their portfolio in Q2 2026, for an estimated $60,512,234
- TWO SIGMA INVESTMENTS, LP added 926,659 shares (+60.1%) to their portfolio in Q2 2026, for an estimated $50,910,645
- MAN GROUP PLC removed 824,261 shares (-86.2%) from their portfolio in Q2 2026, for an estimated $45,284,899
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
TG THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $TGTX recently. We have seen 2 analysts offer price targets for $TGTX in the last 6 months, with a median target of $45.0.
Here are some recent targets:
- Alec Stranahan from B of A Securities set a target price of $20.0 on 07/07/2026
- Emily Bodnar from HC Wainwright & Co. set a target price of $70.0 on 07/06/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
